Tenax Therapeutics Inc. Corporate Update – 22 October 2026
Stock Performance (24‑Hour Period Ending 04:34 PM Central Europe)
- Trading session closed flat at 0 %.
- Current share price: USD 1.69.
- Shares available for trading: 57.3 million.
- Market capitalization: USD 93.4 million.
- 24‑hour trading volume: USD 3.7 million.
- Year‑to‑date change: –15.98 %.
- 200‑day simple moving average: USD 10.51.
- 52‑week high: USD 19.40 (7 September 2026).
- 52‑week low: USD 1.31 (8 October 2026).
Recent Equity Transactions On 21 October 2026, Tenax Therapeutics filed Form 8‑K reporting equity purchases by private investment entities managed by ADAR1 Capital Management, LLC, and its manager Daniel Schneeberger.
- Transactions occurred on three successive dates.
- Purchases involved several hundred thousand shares at progressively higher weighted‑average prices.
- After each transaction, the firm’s holdings increased to several million shares, indicating a growing stake in the company.
- Shares are held directly by the private fund; the ownership reported in the filing is indirect for regulatory purposes.
- No additional corporate actions or financial disclosures were made in the filing.
Related Stock Activity (Last 24 Hours)
| Symbol | Trade Direction | Current Price (USD) | Market Cap (USD mn) | Notes |
|---|---|---|---|---|
| TP | +1.09 % | 8.38 | 110 | Ticketplus reports modest revenue growth, slight increase in sales volume, but misses analyst forecasts. Gross margin near previous level; net earnings below projections due to FX losses and one‑off compensation expenses. Management expects absorption of these items in the next quarter; brokerage lowered earnings outlook and target price while maintaining a neutral rating. |
| QSEA | +0.19 % | 10.71 | 108.6 | Quartzsea Acquisition filed an 8‑K on 20 October 2026, reporting a deposit into its trust account to extend the deadline for consummating its initial business combination by one month (from 19 October to 19 November 2026). The entity is a publicly‑listed shell on Nasdaq (ticker QSEAU). No other material events reported. |
| SSTI | 0 % | 8.40 | 110.6 | Soundthinking’s share price remained unchanged. |
| GNLX | –17.20 % | 1.97 | 112 | Genelux experienced a sharp decline in share price. |
| AKA | +2.49 % | 10.81 | 110.6 | Aka Brands, listed ASX:AKA, reported developments in its gold projects. Inferred JORC resources expanded to over 450,000 ounces at the Irvine Gold Project; St Arnaud Comstock project reached a maiden inferred resource. Production commenced at Fiddlers Creek mine with the Wedderburn processing mill operating under a long‑term offtake agreement. The company remains debt‑free and completed a share placement to support its transition from exploration to production. |
Company Overview Tenax Therapeutics Inc. is a specialty pharmaceutical company focused on biotechnology within the healthcare sector. The company is headquartered in Morrisville, United States, and aims to develop and commercialize products for the critical care market. Its research emphasizes treatments for pulmonary hypertension associated with heart failure and preserved ejection fraction (PH‑HFPf), utilizing levosimendan as a key active ingredient. Additional information is available on the company’s website at www.tenaxthera.com and through its listing on the Nasdaq stock exchange.
